NasdaqGM:IVTY

Stock Analysis Report

Executive Summary

Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.

Risks

  • Invuity has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Invuity's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

NasdaqGM:IVTY

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-20.1%

NasdaqGM:IVTY

9.9%

US Medical Equipment

1.6%

US Market


Share holder returns

IVTYIndustryMarket
7 Day0%0.5%-0.02%
30 Day-0.1%0.09%2.7%
90 Day79.2%2.0%1.4%
1 Year-20.1%-20.1%10.8%9.9%3.8%1.6%
3 Year-39.7%-39.7%69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Invuity's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Invuity undervalued based on future cash flows and its price relative to the stock market?

76.29x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Invuity to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Invuity to establish if it is available at substantial discount.


Price Based on Earnings

Invuity is loss making, we can't compare its value to the US Medical Equipment industry average.

Invuity is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Invuity is loss making, we can't assess if its growth is good value.


Price Based on Value of Assets

Invuity is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Invuity expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

34.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Invuity's revenue is expected to grow significantly at over 20% yearly.

Invuity is not considered high growth as it is expected to be loss making for the next 1-3 years.

Invuity's revenue growth is expected to exceed the United States of America market average.

Unable to compare Invuity's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Invuity's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Invuity will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Invuity performed over the past 5 years?

-15.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Invuity does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Invuity's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Invuity's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Invuity has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Invuity has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Invuity improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Invuity's financial position?


Financial Position Analysis

Invuity is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Invuity's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Invuity's level of debt (1486.2%) compared to net worth is high (greater than 40%).

Unable to establish if Invuity's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Invuity has sufficient cash runway for 1.2 years based on current financial obligations.

Invuity has sufficient cash runway for 1.1 years if financial obligations continue to reduce at historical rates of -8.3% each year.


Next Steps

Dividend

What is Invuity's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Invuity's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Invuity's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Invuity has not reported any payouts.

Unable to verify if Invuity's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Invuity has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Invuity's salary, the management and board of directors tenure and is there insider trading?

1.0yrs

Average management tenure


CEO

Scott Flora (62yo)

0.6yrs

Tenure

US$165,079

Compensation

Mr. Scott D. Flora serves as President of SFlora Consulting LLC since 2016. Mr. Flora has been Interim President and Chief Executive Officer at Invuity, Inc. since March 01, 2018. He served as the Chief Ex ...


Management Age and Tenure

1.0yrs

Average Tenure

54yo

Average Age

The average tenure for the Invuity management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.1yrs

Average Tenure

60yo

Average Age

The tenure for the Invuity board of directors is about average.


Insider Trading

No 3 month insider trading information.


Recent Insider Transactions

BuyUS$004 Oct 18
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares350,975
Max PriceUS$7.40
BuyUS$6,748,29004 Oct 18
GAMCO Investors, Inc.
EntityCompany
Shares916,625
Max PriceUS$7.40
BuyUS$16,373,75524 Sep 18
Gardner Lewis Asset Management LP
EntityCompany
Shares2,228,716
Max PriceUS$7.35

Ownership Breakdown


Management Team

  • Doug Heigel (57yo)

    Senior Vice President of Operations

    • Tenure: 4.1yrs
    • Compensation: US$536.13k
  • Scott Flora (62yo)

    Interim President

    • Tenure: 0.6yrs
    • Compensation: US$165.08k
  • Jim MacKaness (54yo)

    Chief Financial Officer

    • Tenure: 3.2yrs
    • Compensation: US$690.59k
  • Steven Annen (54yo)

    Vice President of Product Management & Strategy

    • Tenure: 2.5yrs
  • Marcia Fish (54yo)

    Chief Human Resources Officer

    • Tenure: 1yrs
  • Sham Shiblaq

    Vice President of Commercial Operations

    • Tenure: 0.4yrs
  • Lauren Budesheim

    Senior Director of Human Resources

    • Tenure: 0.3yrs

Board Members

  • Randy Lipps (61yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$196.50k
  • Bill Burke (59yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$207.50k
  • Greg Lucier (54yo)

    Independent Chairman

    • Tenure: 2.8yrs
    • Compensation: US$223.69k
  • Daniel Wolterman (61yo)

    Director

    • Tenure: 1.1yrs
    • Compensation: US$142.63k
  • Scott Flora (62yo)

    Interim President

    • Tenure: 0.6yrs
    • Compensation: US$165.08k
  • Eric Roberts (54yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: US$190.57k

Company Information

Invuity, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Invuity, Inc.
  • Ticker: IVTY
  • Exchange: NasdaqGM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$177.990m
  • Shares outstanding: 24.09m
  • Website: https://www.invuity.com

Number of Employees


Location

  • Invuity, Inc.
  • 444 De Haro Street
  • San Francisco
  • California
  • 94107
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IVTYNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2015
0IIDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2015

Biography

Invuity, Inc., a medical technology company, develops and markets surgical devices in the United States and Asia. The company through its intelligent photonics technology platform develops single-use and r ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2018/10/23 21:32
End of Day Share Price2018/10/22 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.